^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Purinergic receptor P2Y12 inhibitor

    Related drugs:
    1m
    OPTIMIZE-APT: Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent (clinicaltrials.gov)
    P4, N=3944, Recruiting, Asan Medical Center | Trial completion date: Dec 2028 --> Dec 2032 | Trial primary completion date: Aug 2027 --> Dec 2027
    Trial completion date • Trial primary completion date
    2ms
    DAPTCLTI: Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization (clinicaltrials.gov)
    P3, N=614, Recruiting, Fondation Hôpital Saint-Joseph | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    TICTAVI: Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI) (clinicaltrials.gov)
    P3, N=50, Terminated, University Hospital, Bordeaux | Completed --> Terminated; target number of subjects not reached
    Trial termination
    2ms
    ADONIS-PCI: Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI (clinicaltrials.gov)
    P4, N=1194, Recruiting, Medical University of Gdansk | N=2230 --> 1194 | Trial completion date: Mar 2026 --> Aug 2026 | Trial primary completion date: Mar 2024 --> Jul 2026
    Enrollment change • Trial completion date • Trial primary completion date
    2ms
    CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA) (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    New trial
    2ms
    Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization (clinicaltrials.gov)
    P=N/A, N=130, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Oct 2024 --> Feb 2026
    Trial primary completion date
    2ms
    CLI-06727AA1-03: Cangrelor safety and pharmacodynamics in paediatric subjects with congenital heart disease (2025-523109-14-00)
    P2/3, N=40, Not yet recruiting, Chiesi Farmaceutici S.p.A.
    New P2/3 trial
    2ms
    RC31/23-0369: TicAgreLor versus placebo to prevent cerebral ISCHemia in anEuRysmal low grade SAH A double blinded randomised controlled study (2023-509795-42-00)
    P2/3, N=274, Not yet recruiting, Centre Hospitalier Universitaire De Toulouse
    New P2/3 trial
    2ms
    The Pharmacokinetics and Pharmacodynamics Study of CG-0255 Besylate and Plavix® in Healthy Participants (clinicaltrials.gov)
    P1, N=136, Recruiting, Shanghai CureGene Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    COMFORT-PFO: Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy (clinicaltrials.gov)
    P3, N=32, Not yet recruiting, Columbia University
    New P3 trial
    2ms
    Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel (clinicaltrials.gov)
    P1, N=24, Recruiting, Washington State University | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Aug 2025 --> Aug 2027
    Trial completion date • Trial primary completion date
    2ms
    The Pharmacokinetics and Pharmacodynamics Study of CG-0255 Besylate and Plavix® in Healthy Participants (clinicaltrials.gov)
    P1, N=136, Not yet recruiting, Shanghai CureGene Pharmaceutical Co., Ltd.
    New P1 trial